119 filings
Page 2 of 6
8-K
czknaz9
16 May 23
X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market
4:24pm
8-K
ti22txf5629lizxqs262
4 May 23
Regulation FD Disclosure
4:07pm
8-K
0uhy02i75ate0niyk
4 May 23
X4 Pharmaceuticals Reports First-Quarter 2023 Financial
9:05am
8-K
raxxcn1maau 1dkub
4 May 23
X4 Pharmaceuticals Reports First-Quarter 2023 Financial
6:42am
8-K
eh6kzl6fw1 gwr
21 Mar 23
Regulation FD Disclosure
5:02pm
8-K
vdlby99zod te4vj00x
21 Mar 23
X4 Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial
7:09am
8-K
jh7rm8z9 7wzw6
10 Mar 23
Other Events
4:05pm
8-K
s6jk59ig
6 Jan 23
Entry into a Material Definitive Agreement
5:26pm
8-K
ewc6jv8ghx5r
5 Jan 23
Regulation FD Disclosure
4:10pm
8-K
u1fmxsqvcgqh0mt
23 Dec 22
Departure of Directors or Certain Officers
4:02pm
8-K
z22pc c64h2ddkisi0
9 Dec 22
X4 Pharmaceuticals Announces Proposed Public Offering
8:46am
8-K
e39zsiuu6cjrurq2jz
29 Nov 22
X4 Pharmaceuticals Announces Positive Top-Line Results from 4WHIM Global, Pivotal Phase 3 Trial of Once-Daily, Oral Mavorixafor in WHIM Syndrome
4:05pm
8-K
eg9u j27h
9 Nov 22
Departure of Directors or Certain Officers
4:18pm
8-K
fomg5p4osbw
3 Nov 22
X4 Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
7:21am
8-K
y7j czodq1g4zn
4 Oct 22
Regulation FD Disclosure
4:42pm
8-K
45n gvliz
27 Sep 22
Regulation FD Disclosure
7:53am
8-K
535p2xginouqn0zd
1 Sep 22
Material Modifications to Rights of Security Holders
4:51pm
8-K
e740lc3242y9oika
5 Aug 22
Regulation FD Disclosure
8:10am
8-K
q4w1 1vui0
4 Aug 22
X4 Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
7:29am
8-K
wzqj2v
29 Jul 22
Departure of Directors or Certain Officers
4:05pm